But toxicity could hold back Destiny-Breast06's ability to change clinical practice.

Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Meanwhile, Lilly gets in on the next-gen KRAS action.

The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

But will the FDA accept the surrogate endpoint used in ASC4First?